% | $
Quotes you view appear here for quick access.

Neoprobe Corporation Common Sto Message Board

  • zinsinus zinsinus Jun 6, 2011 11:21 AM Flag

    From AF blog

    adam feuerstein:
    NEOP -- a view from the short side... Here's what one short seller is saying about the Lymphoseek data...

    Concordance with Vital Blue dye for both the -05 and -09 studies remained 100% and should not be surprising. Key is the per patient data as that’s all that’s really clinically relevant.

    As previously released, the per node assessment showed that in 133 patients in the -09 study Lymphoseek failed to detect 0% of LN’s whereas Vital blue dye missed 25% or 33 patients. Key question was are these simply nodes down stream from the sentinel node al;ready detected by blue dye….if so then ID’ing added nodes is meaningless.

    In fact in the per patient assessment the company had to POOL both the 0-5 and 09 studies in order to demonstrate any findings and did not break out the individual studies alone. Further more while the Lymphoseek Failed detection rate remained at 0% the vital bue dye only missed 7.3% of 4 patients…..way down from the 33 in the 09 study alone on a per node basis…..this basically confirms that the vast majority of cases that Lymphoseek picked up were simply added nodes beyond the sentinel node…..which is clinically irrelevant. Plus to hit a p value of <0.044…..barely stat sig…..they had to pool the studies…..which you can’t do from the FDA’s point of view.

    SortNewest  |  Oldest  |  Most Replied Expand all replies